The variants of SOX17 in pediatric PAH include LGD variants, damaging missense variants, and heterozygous SOX17 mutation, and LGD variants (33.3%–60%) and damaging missense variants (33.3%–40%) as the predominant mutations (Zhu et al., 2018b; Zhu et al., 2019; Wang et al., 2021; Welch et al., 2021). This evidence concerns the gene SOX17 and pulmonary arterial hypertension.